DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS - Concepedia

Concepedia

Publication | Open Access

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS

DOI Full Paper Access

181

Citations

17

References

2018

Year

Howard Trachtman, Peter J. Nelson, Sharon G. Adler, Kirk N. Campbell, Abanti Chaudhuri, Vimal K. Derebail, Giovanni Gambaro, Loreto Gesualdo, Debbie S. Gipson, Jonathan Hogan,

Journal of the American Society of Nephrology

Abstract

Patients with FSGS achieved significantly greater reductions in proteinuria after 8 weeks of sparsentan versus irbesartan. Sparsentan was safe and well tolerated.

References

	Year	Citations

Page 1